Protein Expression - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The protein expression market size is expected to grow from USD 3.12 billion in 2025 to USD 3.37 billion in 2026 and is forecast to reach USD 4.98 billion by 2031 at 8.12% CAGR over 2026-2031. This report is Segmented by Product & Services (Reagents & Kits [Cell-Free Expression, Bacterial Expression, and More], Services, and Other Products), Application (Therapeutic, Industrial Enzymes, and More), End User (Academia & Research Institutes, Cros / CDMOs, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Protein Expression Market Trends and Insights

Rising R&D Investments by Large-Cap Pharma

Industry majors are investing heavily in expression infrastructure; Thermo Fisher Scientific alone allocated USD 2 billion for U.S. expansion that targets both capacity and next-generation process innovation. Such capital flows align with the fact that biologics now account for nearly 70% of biopharmaceutical sales, making dependable protein output a strategic imperative. M&A activity, illustrated by Roche’s USD 1 billion agreement to acquire Poseida Therapeutics, concentrates valuable expression know-how within top tier firms. Start-ups also benefit; ExpressionEdits raised USD 13 million to engineer higher-fidelity proteins, signalling broad confidence in the space. As this funding surge translates into new pilot and commercial facilities, the protein expression market experiences stronger order books and faster technology refresh cycles.

Expansion of Therapeutic Biologics Pipeline

WuXi Biologics’ 698 active programs, including 51 late-phase projects, highlight the unprecedented scale of clinical development that hinges on sophisticated expression systems. Growing FDA approvals of monoclonal antibodies and the advent of gene-edited cell therapies, such as CASGEVY under Lonza’s supply agreement, intensify demand for platforms that can handle complex post-translational requirements. Antibody-drug conjugates and bispecific formats require high-yield mammalian systems, while microbial platforms are being re-engineered to deliver plasmid DNA at commercial scale. This broad modality mix stretches existing capacity and drives multiyear outsourcing contracts, fuelling consistent revenue streams across equipment, reagents, and services. Geographic diversification of clinical trials reinforces the need for local manufacturing footprints in Asia-Pacific and Europe, further widening the protein expression market.

Capital-Intensive High-Throughput Systems

Scaling from 10 to 288 recombinant proteins per week necessitates liquid-handling robots, parallel bioreactors, and integrated purification skids that carry heavy upfront costs. Platforms such as the Protein Expression and Purification Platform rely on fully automated HEK and CHO lines, requiring specialised facilities, ongoing maintenance, and skilled operators. Downstream processing outlays can consume up to 60% of total development budgets, stretching the finances of smaller firms and slowing adoption in lower-income regions. While low-cost DIY reactors offer limited relief, they sacrifice throughput and compliance readiness. This financial barrier narrows supplier diversity and tempers the near-term growth of the protein expression market in capital-constrained geographies.

Other drivers and restraints analyzed in the detailed report include:

• Government-Funded Multi-Omics Initiatives
• AI-Optimised Codon Usage Accelerating Yield
• Limited Post-Translational Modification Fidelity

Segment Analysis

Reagents & Kits captured 46.80% protein expression market share in 2025, underlining their status as indispensable inputs across every workflow, from vector construction to final purification. Service providers are gaining momentum; the segment is forecast to post a 12.07% CAGR through 2031 as developers outsource complex or high-volume programs to partners with proprietary cell lines and GMP suites. KBI Biopharma secured USD 250 million worth of long-term mammalian production contracts that illustrate sustained demand for external expertise.

Innovation within reagents remains brisk: Bioneer’s ExiProgen system and newer cell-free formulations cut expression timelines while preserving yields. Meanwhile, multi-modality CDMO deals, reported by BioProcess International, broaden service menus to include cell-free and microbial options, signalling that service revenues will outpace reagent growth as biologic complexity rises. Collectively, these forces deepen the protein expression market, creating parallel revenue streams from consumables and turnkey outsourcing.

Complete Report Scope:

• By Product & Services
  • Reagents & Kits
    • Cell-free Expression
    • Bacterial Expression
    • Yeast Expression
    • Algal Expression
    • Insect Expression
    • Mammalian Expression
    • Plant-based Expression
  • Services
  • Other Products
• By Application
  • Therapeutic
  • Industrial Enzymes
  • Research & Discovery
  • Agricultural Biotechnology
• By End-user
  • Academia & Research Institutes
  • Biotechnology & Pharmaceutical Companies
  • CROs / CDMOs
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.55% protein expression market share in 2025 on the strength of deep pharmaceutical pipelines, venture capital networks, and an enabling policy environment. The NSF’s USD 40 million protein design program and ARPA-H’s vaccine-centric initiatives provide long-term demand visibility. Company-level moves - including Thermo Fisher’s USD 3.1 billion acquisition of Olink - bolster analytical throughput and are positioning the region as a global proteomics hub. Canada and Mexico contribute scale-up and fill-finish services that complement U.S. capacity, while streamlined regulatory pathways encourage cross-border trials.

Asia-Pacific is forecast to deliver the highest regional CAGR at 11.45% through 2031, propelled by harmonised regulations, cost-competitive capacity, and government incentives for biologics self-sufficiency. China leads investments, evidenced by WuXi Biologics’ 37.7% non-COVID revenue growth and new microbial platforms designed for recombinant protein and plasmid DNA. Japan and South Korea supply cutting-edge automation, while India and Australia offer cost-effective, GMP-ready infrastructures. Regional governments back precision fermentation firms to address food security, expanding end-markets beyond therapeutics.

Europe shows steady mid-single-digit growth anchored by established manufacturing hubs and a rigorous yet predictable regulatory framework. Lonza’s Netherlands facility, key to the CASGEVY gene-edited cell therapy, confirms Europe’s ability to handle novel modalities at commercial scale. Germany, the United Kingdom, and France remain R&D powerhouses, and Eastern European nations add capacity with competitive labor costs. Ongoing emphasis on sustainability feeds demand for plant-based and precision-fermented proteins, aligning policy goals with commercial adoption.

List of Companies Covered in this Report:

• Thermo Fisher Scientific
• Merck
• Agilent Technologies
• Takara Bio
• QIAGEN
• Bio-Rad Laboratories
• New England Biolabs
• Promega
• GenScript Biotech
• Lonza Group
• Abcam
• Danaher
• Bio-Techne
• Sino Biological
• Bioneer Corp
• Oxford Expression Technologies
• Synthetic Genomics
• Charles River
• Evitria AG

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support